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atherogenically potent macrophages and/or lipoprotein par-
ticles; these associations could indicate a plausible linkage 
between apoE polymorphism and ceramide metabolism, lead-
ing to adverse plasma LDL metabolism and atherogenesis.  
In conclusion, new evidence from plasma ceramides links 
apoE polymorphism with an increased risk of CAD and ex-
tends our understanding of the role of apoE in health and 
disease.—Karjalainen J-P., N. Mononen, N. Hutri-Kähönen, 
M. Lehtimäki, M. Hilvo, D. Kauhanen, M. Juonala, J. Viikari, 
M. Kähönen, O. Raitakari, R. Laaksonen, and T. Lehtimäki. 
New evidence from plasma ceramides links apoE polymor-
phism to greater risk of coronary artery disease in Finnish 
adults. J. Lipid Res. 2019. 60: 1622–1629.
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apoE is a glycoprotein of 299 amino acids with a key role 
in regulating plasma lipid levels. The three common allelic 
variants of the apoE gene, 2, 3, and 4, determined by 
two SNPs at locus 19q13.31, rs429358 and rs7412, code 
Abstract apoE, a key regulator of plasma lipids, mediates 
altered functionalities in lipoprotein metabolism and thus 
affects the risk of coronary artery disease (CAD). The sig-
nificance of different apoE polymorphisms remains unclear; 
although the 4 allele is clearly associated with increased 
cholesterol levels (which inform CAD risk), direct studies 
about apoE polymorphisms on CAD risk and development 
have yielded controversial results. Furthermore, certain 
species of ceramides—complex lipids abundant in plasma 
LDL—are markers of increased risk of myocardial infarc-
tion and cardiovascular death. Using a high-throughput MS 
approach, we quantified 30 molecular plasma ceramide 
species from a cohort of 2,160 apoE-genotyped (rs7412, 
rs429358) young adults enrolled in the population-based 
Cardiovascular Risk in Young Finns Study. We then searched 
this lipidome data set to identify new indications of pathways 
influenced by apoE polymorphisms and possibly related to 
CAD risk. This approach revealed a previously unreported 
association between apoE polymorphism and a consistently 
documented high-risk CAD marker, Cer(d18:1/16:0). Com-
pared with the apoE 3/3 reference group, plasma levels of 
apoE 4 were elevated and those of apoE 2 were lowered in 
all subjects without evidence of apoE-by-sex interactions. 
apoE associated with seven ceramides that are connected to 
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Plasma ceramides link apoE polymorphism to CAD risk 1623
respectively three protein isoforms: E2, E3, and E4. Of the 
six forming apoE genotypes (2/2, 3/2, 3/3, 4/2, 4/3, 
and 4/4), the homozygote parent genotype 3/3 is the 
most prevalent, and the protein isoform E3 associates with 
normal/average plasma lipid levels (1). Despite the early 
established association of the 4 allele with elevated serum 
total cholesterol and LDL cholesterol (LDL-C) (2, 3), as 
well as the generally recognized causality of high serum to-
tal cholesterol and LDL-C with coronary artery disease 
(CAD) (4), studies investigating the significance of apoE 
polymorphism on the susceptibility and development of 
CAD have led to controversial results (5–8). However, it 
has been shown that genetic components affect atheroscle-
rosis and CAD risk (9, 10). In a Finnish population with 
higher-than-average incidence of atherosclerosis and na-
tionwide prevalence of the 4 allele (2), indications that 4 
is linked to the risk of atherosclerosis and CAD have been 
reported (11). On the other hand, 2 has been shown to 
reduce carotid artery intima-media thickness and coronary 
artery calcification across multiple ethnicities, including 
Finns (12, 13). Altogether, further research is required to 
clarify the role of apoE in the metabolic pathways and 
mechanisms of atherogenesis.
In predicting atherosclerosis and its complications, pre-
vious studies have concluded that the traditionally applied 
standard lipid-panel parameters are inadequate for identi-
fying patients at different risks; therefore, novel, more spe-
cific risk markers have been investigated and found with 
state-of-art lipidomic and metabolomic methods (4). In the 
current work we concentrate on the effects of apoE poly-
morphism on plasma ceramides, with an emphasis on pre-
dicted CAD risk. Unlike with basic lipids, evidence of the 
associations of apoE polymorphism with plasma ceramides, 
or lipidomics in general, is very limited.
To allow for a comprehensive analysis, we quantified 30 
molecular plasma ceramide species. Certain ceramides 
have consistently been reported as high-risk markers of 
CAD and adverse cardiac outcomes, indicated among CAD 
patients with an established disease (14–18), as well as at 
the population level in incident events (19, 20). The aim of 
our study was to search for novel linkages between apoE 
polymorphism and risk of CAD by means of plasma cerami-
des. By implementing a population-based cohort of basi-
cally healthy, relatively young adults, we sought to recognize 
prevailing genotype-related differences prior to adverse 
manifestations, especially in the markers previously associ-
ated with atherogenesis. With our findings we expect to 
extend our current understanding of the role of apoE in 
health and disease.
MATERIALS AND METHODS
Study population and data sources
The Cardiovascular Risk in Young Finns Study (YFS) is a Finn-
ish longitudinal general population study on the evolution of car-
diovascular risk factors from childhood to adulthood (21). The 
study began in 1980, when 3,596 children and adolescents aged 3, 
6, 9, 12, 15, and 18 years were randomly selected from five univer-
sity hospital catchment areas in Finland. In 2007, 2,200 participants 
aged 30–45 years attended the 27-year follow-up. Of these 
subjects, we included those for whom the apoE genotype data and 
at least 80% of the lipidomic parameters were available. There-
fore, 2,160 participants contributed to the cross-sectional associa-
tion analyses of apoE genotype and plasma ceramide profile. The 
YFS was approved by the 1st ethical committee of the Hospital 
District of Southwest Finland and by local ethical committees (1st 
Ethical Committee of the Hospital District of Southwest Finland, 
Regional Ethics Committee of the Expert Responsibility area of 
Tampere University Hospital, Helsinki University Hospital Ethical 
Committee of Medicine, The Research Ethics Committee of the 
Northern Savo Hospital District and Ethics Committee of the 
Northern Ostrobothnia Hospital District). The study protocol of 
each study phase corresponded to the proposal by the World 
Health Organization. All subjects gave written informed consent, 
and the study was conducted in accordance with the Helsinki dec-
laration. At prior YFS follow-ups, informed consent of every par-
ticipant under the age of 18 years was obtained from a parent 
and/or legal guardian.
Clinical and biochemical measurements and their use in 
statistical standardization
To eliminate the effects of the most probable error sources, a 
comprehensive set of clinical background information was ana-
lyzed as confounding candidates. The effect of BMI was consid-
ered by including it in the final regression models as a covariate. 
Based on questionnaires, daily smoking (yes/no), hormonal birth 
control of women (yes/no), cholesterol-lowering medication 
(yes/no), and socioeconomic status were all tested as covariates to 
have negligible or zero effect on the apoE -values. The distribu-
tions of alcohol consumption (daily portions based on a question-
naire, with one portion equaling 12 g of pure alcohol) and 
physical activity index [graded 5–15, where higher values indicate 
greater physical activity; the evaluation method has been de-
scribed elsewhere (22)] were well comparable in every analyzed 
apoE subgroup and therefore not confounding, which was also 
confirmed with covariate analyses. In addition, there were only a 
few pregnant women, and persons with diagnosed diabetes (eval-
uated with questionnaires) and their distributions did not differ 
in the analyzed subgroups. Parameters describing the cardiovas-
cular status, such as systolic blood pressure (defined as an average 
of three consecutive measurements with a random-zero mercury 
sphygmomanometer), hypertension (based on a questionnaire 
for medically diagnosed hypertension), and high-sensitivity 
C-reactive protein (CRP) (measured with an Olympus AU400 auto-
matic analyzer) might well reflect variations in lipidomics, that is, 
could be considered more as consequential rather than con-
founding factors. Nevertheless, differences in these measures be-
tween the subgroups were also found to be minor, a significant 
majority of the study population being basically healthy. Based on 
the described background analyses and to avoid unnecessary selec-
tion error, additional exclusions were not made in the final analyses. 
The effect of possible information bias may well be neglected in 
our results when comparing the subgroups to each other, with the 
bias (if any) being presumably distributed comparably.
Serum concentrations of standard lipids
Levels of total cholesterol, LDL-C, HDL cholesterol (HDL-C), 
triglycerides, and apoA-I and apoB were measured as background 
descriptive data with methods described elsewhere (23).
apoE genotyping
apoE alleles (2, 3, 4) were determined on the basis of SNP 
rs7412 and rs429358 haplotypes. Genomic DNA was extracted 
from peripheral blood leukocytes by using the QIAamp DNA 
Blood Minikit and automated biorobot M48 extraction (Qiagen, 
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Hilden, Germany). Genotyping was performed by using Taqman 
SNP genotyping assays and the ABI Prism 7900HT Sequence De-
tection System (Applied Biosystems, Foster City, CA). As a quality 
control, water controls, random duplicates, and known control 
samples were run in parallel with unknown DNA samples.
Plasma lipidomic profiling
Ceramide quantification for the stored plasma samples was per-
formed at Zora Biosciences Oy (Espoo, Finland). Lipid extraction 
was based on a previously described method (24). In brief, 10 µl 10 
mM 2,6-di-tert-butyl-4-methylphenol in methanol was added to 10 
l of sample, followed by 20 µl of internal standards (Avanti Polar 
Lipids Inc., Alabaster, AL) and 300 µl chloroform-methanol (2:1; 
v:v) (Sigma-Aldrich GmbH, Steinheim, Germany). Samples were 
mixed and sonicated in a water bath for 10 min, followed by a 40 
min incubation and centrifugation (15 min at 5,700 g). The upper 
phase was transferred and evaporated under nitrogen. Extracted 
lipids were resuspended in 100 µl water-saturated butanol and 
sonicated in a water bath for 5 min. Methanol (100 µl) was added 
to the samples before the extracts were centrifuged for 5 min at 
3,500 g, and finally the supernatants were transferred to the analy-
sis plate for mass spectrometric analysis. Details of mass spectro-
metric analyses have also been described in detail previously (25). 
The analyses were performed on a hybrid triple-quadrupole/lin-
ear ion trap mass spectrometer (QTRAP 5500; AB Sciex, Concord, 
Canada) equipped with ultra-high-performance liquid chromatog-
raphy (Nexera-X2; Shimadzu, Kyoto, Japan). Chromatographic 
separation of the lipidomic screening platform was performed on 
an Acquity BEH C18, 2.1 × 50 mm i.d. 1.7 µm column (Waters 
Corporation, Milford, MA). The data were collected using a sched-
uled multiple-reaction monitoring algorithm, and the data were 
processed using Analyst and MultiQuant 3.0 software (AB Sciex).
Statistical methods
All statistical analyses were conducted with R version 3.1.2 
(https://www.r-project.org). To facilitate comparisons across all 
lipidomic measures, association magnitudes (-values) are re-
ported in scaled SD fractions (units) of normalized, ln-transformed 
lipid concentrations. In sex-stratified cross-sectional analyses, 
separate sex-specific scaling was applied to lipidomic measures.
Cross-sectional associations of apoE genotype and serum ce-
ramide profile were analyzed using linear multivariable regres-
sion models, with each lipidomic measure as the outcome and 
apoE genotype as the main explanatory value. Regression models 
were adjusted for age and BMI. The effect of sex was analyzed in 
both ways, with models stratified by sex and models with sex as a 
covariate. The apoE × BMI interaction was tested to have a negli-
gible or zero effect on the apoE -values and was therefore ex-
cluded from the final models. Prior to testing the interaction 
effects of BMI, measures of BMI were mean-centered. Similarly, 
apoE × sex and apoE × age interactions were excluded from the 
final models for not showing an effect within any lipidomic mea-
sure (P > 0.05). apoE genotype was included in the model as a 
categorical variable. First, the overall effect of apoE genotype on 
the linear fit was F-tested by implementing the Benjamini-Hochberg 
procedure (26) in false discovery rate (FDR) correction and set-
ting the limit at P < 0.05. After that, apoE genotypes were com-
pared with each other post hoc with t-tests (implementing FDR 
correction), the values of which were inherited from the linear 
regression function (lm) in R. To allow for a better comparison of 
the apoE groups, 95% CIs were also calculated.
Data availability statement
The data sets generated and/or analyzed during this study 
are not publicly available due to restrictions imposed by Finnish 
legislation, as the contained information could compromise 
research participant privacy and consent. However, data sharing 
is possible upon reasonable request, and all decisions are made by 
the YFS Publication and Data Sharing Board.
RESULTS
Characteristics of cross-sectional analyses
The frequencies of different apoE genotypes, as well as 
the summary of the descriptive data in the YFS study popu-
lation in the 2007 follow-up, are presented in Table 1. The 
P values across apoE genotypes are given in supplemental 
Table S1.
Cross-sectional associations of the apoE genotype within 
measured ceramides
Due to small subgroups of apoE 2/2, 4/2, and 4/4 in 
our population-based cohort (see Table 1), apoE geno-
types were clustered into three subgroups for better statisti-
cal comparison: the reference group 3/3 as well as 2+ 
(consisting of 2/2 and 3/2) and 4+ (including all 4 
carriers: 4/2, 4/3, and 4/4). The cross-sectional associ-
ations of apoE genotypes within 30 quantified plasma 
ceramides (and three calculated ceramide ratios) for all 
subjects are illustrated in Fig. 1. The complete statistics of 
Fig. 1, including exact P values, are given in supplemental 
Table S2. As illustrated in supplemental Table S3, the ex-
clusion of the 4/2 subgroup from the analyses did not 
have a major effect on the results. In addition, the com-
plete results of apoB, LDL-C, and HDL-C concentration-
adjusted analyses are provided in supplemental Tables 
S4–S6, respectively. Furthermore, the results from inflam-
matory marker-association analyses (high-sensitivity CRP) 
are shown in supplemental Table S7. There were no apoE × 
sex interactions found in relation to any studied measure 
(P > 0.05), justifying the main analyses being performed 
with all subjects combined.
Based on multivariate regression analyses of all subjects, 
six ceramide species (see Fig. 1) showed an association 
over apoE genotypes with F-tested P < 0.05 after FDR cor-
rection. In post hoc comparisons of all subjects against the 
reference group 3/3, with FDR corrected P < 0.05, the 
high-risk CAD ceramide Cer(d18:1/16:0) differed both in 
apoE 2+ and 4+ subgroups, indicating lower levels in the 
2+ and elevated levels in the 4+ subgroup compared with 
the reference group 3/3. In addition, three ceramides, 
Cer(d16:1/16:0), Cer(d16:1/18:0), and Cer(d18:2/16:0), 
differed in the 2+ subgroup, showing lower plasma levels 
than in the 3/3 and 4+ subgroups. Moreover, one ce-
ramide, Cer(d18:2/22:0), had an elevated plasma level in 
the 4+ subgroup compared with the most common 3/3 
group.
In sex-stratified analyses, the high-risk CAD ceramide 
Cer(d18:1/16:0) showed an association with apoE geno-
types both in women and men (see Fig. 2). In addition, 
the post hoc analysis compared with 3/3 showed differ-
ences of Cer(d18:1/16:0) in 2+ women as well as 4+ men 
(P = 0.005 and P = 0.01 prior to FDR correction, respec-
tively), as also indicated by the 95% CI in Fig. 2 (see 
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exact FDR-corrected P values in supplemental Table S8). 
Moreover, the F-tested association (P < 0.05 after FDR 
correction) of another well-established high-risk CAD 
ceramide, Cer(d18:1/18:0), was found in women only 
(Fig. 2), not in all subjects (Fig. 1) or men.
Cross-sectional associations of the apoE genotype within 
measured sphingomyelins
The cross-sectional associations of 41 plasma sphingomy-
elin species over apoE genotypes in all subjects were also 
analyzed. The complete statistics of these analyses are pre-
sented in supplemental Table S9. Twenty-one sphingomy-
elin species associated with apoE genotypes, with F-tested 
P < 0.05 after FDR correction; of the species tested, 
SM(34:1) showed the strongest association. In the post hoc 
tests compared with 3/3 and with FDR-corrected P < 0.05, 
the levels of 14 sphingomyelin species were lower in the 2 
carriers; again, SM(34:1) was the top hit. None of the 
sphingomyelins quite reached the same statistical limit 
after FDR correction in the 4+ subgroup.
TABLE 1. Frequencies of different apoE genotypes with summary descriptive data in the  
YFS cohort in the 2007 follow-up
All 2/2 3/2 3/3 4/2 4/3 4/4
Subjects 2,160 4 (0.2) 142 (6.6) 1,241 (57.5) 41 (1.9) 651 (30.1) 81 (3.8)
Males 974 (45.1) 2 (0.2) 56 (5.7) 568 (58.3) 17 (1.7) 296 (30.4) 35 (3.6)
Females 1,186 (54.9) 2 (0.2) 86 (7.3) 673 (56.7) 24 (2.0) 355 (29.9) 46 (3.9)
Age (years) 37.6 (5.0) 36.0 (7.4) 36.9 (5.1) 37.7 (5.0) 38.6 (4.0) 37.5 (5.1) 38.0 (4.8)
BMI (kg/m2) 26.0 (4.8) 36.8 (17.2) 25.5 (4.8) 26.0 (4.6) 25.9 (4.5) 26.0 (4.8) 26.3 (5.3)
Daily smokers 398 (18.4) 1 (25) 21 (14.8) 229 (18.5) 6 (14.6) 127 (19.5) 14 (17.3)
Daily alcohol 
consumption  
(g ethanol)
11.3 (17.0) 4.7 (6.5) 12.4 (18.2) 11.9 (18.8) 9.8 (13.9) 10.0 (13.1) 11.5 (13.7)
Cholesterol-lowering 
medication
45 (2.1) 0 (0.0) 2 (1.4) 23 (1.9) 2 (4.9) 15 (2.3) 3 (3.7)
Diabetes mellitus type 2 22 (1.0) 0 (0.0) 2 (1.4) 15 (1.2) 0 (0.0) 5 (0.8) 0 (0.0)
Hypertension 123 (5.7) 2 (50.0) 4 (2.8) 67 (5.4) 1 (2.4) 45 (6.9) 4 (4.9)
Total cholesterol 
(mmol/l)
5.05 (0.90) 4.12 (0.76) 4.49 (0.82) 5.03 (0.89) 4.68 (0.82) 5.22 (0.89) 5.28 (0.84)
LDL-C (mmol/l) 3.15 (0.81) 1.94 (0.30) 2.48 (0.65) 3.12 (0.79) 2.76 (0.68) 3.36 (0.80) 3.30 (0.76)
HDL-C (mmol/l) 1.34 (0.33) 1.17 (0.17) 1.41 (0.37) 1.35 (0.33) 1.35 (0.37) 1.31 (0.31) 1.35 (0.41)
Triglycerides (mmol/l) 1.40 (0.93) 2.22 (0.87) 1.45 (1.00) 1.38 (0.93) 1.36 (0.97) 1.39 (0.82) 1.70 (1.43)
apoB (g/l) 1.02 (0.26) 0.79 (0.16) 0.87 (0.26) 1.01 (0.26) 0.91 (0.23) 1.07 (0.26) 1.09 (0.25)
apoA-I (g/L) 1.60 (0.26) 1.60 (0.22) 1.66 (0.30) 1.61 (0.26) 1.59 (0.25) 1.57 (0.24) 1.60 (0.28)
Values are means (SDs) or n (%). The P values across apoE genotypes are given in supplemental Table S1.
Fig. 1. apoE effects on 30 plasma ceramides and 3 ceramide ratios in all subjects (n = 2,160) of the YFS cohort in the 2007 follow-up. Re-
gression models were adjusted for age, BMI, and sex. Regression -coefficients (x-axis) indicate in SD units the change in the lipid measure 
over apoE genotype subgroups (2+, 3/3, 4+). The most common 3/3 subgroup (n = 1,241) is set at the origin (zero SD) and compared 
post hoc with 2+ (squares) and 4+ (circles) subgroups. -values with 95% CIs are scaled to SD increments from normalized (i.e., ln-trans-
formed) lipid measures. *F-tested effect of apoE with P < 0.05 after FDR correction in the regression model. The post hoc difference with 
P < 0.05 after FDR correction from 3/3 is indicated with colors (blue: 2+; red: 4+). The apoE 2+ subgroup (n = 146) includes 2/2 and 
3/2, and the apoE 4+ subgroup (n = 773) includes 4/2, 4/3, and 4/4.
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DISCUSSION
We investigated the associations of apoE polymorphism 
with plasma ceramide species with an emphasis on previ-
ously reported CAD-risk-related ceramide species. The re-
sults of this study show for the first time an association 
between apoE genotypes and a high-risk CAD ceramide, 
Cer(d18:1/16:0). Cer(d18:1/16:0) has consistently been 
connected to an elevated risk of cardiovascular death 
(16–18), major adverse cardiovascular events (14, 15), and 
vulnerable plaque characteristics (15) among patients with 
established CAD, as well as to incident major adverse car-
diovascular events among healthy populations (19, 20). 
Moreover, elevated plasma levels of Cer(d18:1/16:0) have 
previously been reported among patients with stable CAD 
compared with healthy controls (27). Reported data on 
subclinical atherosclerotic associations of Cer(d18:1/16:0), 
or ceramides in general, is very limited. Nevertheless, 
Cer(d18:1/16:0) has been linked to an increased risk of 
carotid artery plaques (28), and SM(34:1), a precursor 
molecule of Cer(d18:1/16:0), has been linked to increased 
carotid artery intima-media thickness (29). Our analyses 
(supplemental Table S7) also indicate an association of 
Cer(d18:1/16:0) with elevated high-sensitivity CRP levels. 
In addition to Cer(d18:1/16:0), associations with apoE 
genotypes were indicated in six other ceramide species as 
well. These results suggest a novel linkage between apoE 
polymorphism, lipid metabolism, and CAD, as discussed 
briefly in the following paragraphs. A more detailed review 
of previously presented, relevant pathophysiological mech-
anisms is provided in the supplemental Discussion.
Previous genetic-wide association studies have mapped 
the apoE locus to the sphingolipid metabolism pathway 
(30), which is also the major hub for ceramide metabolism 
(31). Inflammatory conditions such as atherosclerosis may 
increase the production of ceramides (32). Ceramides are 
mainly generated through the SMase pathway, which 
breaks downs sphingomyelin in the cell membrane and re-
leases ceramides (32). Alternatively, ceramides can be gen-
erated via a de novo pathway from palmitate, serine, and a 
covalently linked fatty acid that is added to the molecule by 
ceramide synthase in all cell types, with the liver being an 
active site of circulating ceramide production (33, 34). A 
variety of cell types present in atherosclerotic lesions, in-
cluding macrophages and endothelial cells, secretes SMase 
(35). In plasma, ceramides are bound to lipoproteins and 
are particularly abundant in LDL (36). Moreover, LDL iso-
lated from human plasma has also been reported to possess 
SMase activity (37) that is capable of catalyzing the forma-
tion of ceramides in the adjacent lipoproteins as well (38).
Ceramides have been found to enrich the LDL of ath-
erosclerotic lesions compared with plasma LDL (39). 
Elevated sphingolipid content (including certain-risk 
ceramides) of LDL particles (40), as well as macrophage-
derived SMase (32, 41), have been shown to promote the 
aggregation of LDLs and VLDLs. Aggregated lipoprotein 
particles are prone to accumulate within the arterial in-
tima, increase their uptake by macrophages, and thus pro-
mote atherosclerotic plaque formation, as well as future 
CAD death (32, 40). In addition, macrophages loaded with 
oxidized LDLs are demonstrated to contain more intracel-
lular ceramides, with Cer(d18:1/16:0) and Cer(d18:1/18:0) 
Fig. 2. apoE effects on 30 plasma ceramides and 3 ceramide ratios in men (n = 974) and women (n = 1,186) of the YFS cohort in the 2007 
follow-up. Regression models are adjusted for age and BMI. Regression -coefficients (x-axis) indicate in SD units the change in the lipid 
measure over apoE genotype subgroups (2+, 3/3, 4+). The most common 3/3 subgroup (n = 568 men; n = 673 women) is set at the ori-
gin (zero SD) and compared post hoc with 2+ (squares: men; circles: women) and 4+ (triangles: men; diamonds: women) subgroups. 
-values with 95% CIs are scaled to SD increments from normalized (i.e., ln-transformed) lipid measures. The F-tested effect of apoE with P < 0.05 
after FDR correction in the regression model is indicated with an asterisk for men and an “x” for women. The apoE 2+ subgroup (n = 58 men; 
n = 88 women) includes 2/2 and 3/2, and the apoE 4+ subgroup (n = 348 men; n = 425 women) includes 4/2, 4/3, and 4/4.
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being among the reported species (42). On the other 
hand, the deficiency and/or inhibition of the LDL recep-
tor-degrading PCSK9 enzyme has been found to decrease 
certain plasma ceramide levels, including Cer(d18:1/16:0) 
and Cer(d18:1/18:0) (43, 44), as well as lower certain 
ceramide contents in LDL and VLDL particles, including 
all of the seven ceramide species we found to be associated 
with apoE genotypes (43). Supplemental Tables S4 and S5 
further indicate a strong connection between these cerami-
des and apoB-containing LDL, as well as VLDL (and IDL), 
particles, whereas associations with HDL are weak to none 
(supplemental Table S6). A consistent association of apoE 
polymorphism with all of the apoB-containing lipoproteins 
along with their subfractions have been shown recently in 
the same YFS cohort (45). Altogether, ceramides would 
seem to be a plausible and novel common nominator in 
the abundantly investigated chain of apoE polymorphism, 
plasma LDL metabolism, and the risk of CAD.
In addition to the SMase pathway, it may be possible that 
the altered concentrations of certain ceramide species 
could also result from changes in the de novo pathway due 
to altered ceramide synthase activities. For example, the de 
novo pathway has been reported to be influenced by high-
fat-diet administration (especially saturated fatty acids) 
and/or palmitate treatment, which in several reference 
studies has been shown to increase molecular ceramide 
contents, most consistently C16:0 and C18:0 species, inde-
pendent of tissue or cell type (46).
To our knowledge, previous studies of apoE interactions 
with sphingolipid metabolism in atherogenesis have not 
investigated the effect of apoE polymorphism. However, 
apoE has been observed to increase the macrophage up-
take of ceramides (47). Moreover, apoE has been reported 
to prevent SMase-induced hydrophobic interaction and ag-
gregation of lipoproteins (48). In addition, it has been 
demonstrated that the majority of apoE in atherosclerotic 
lesions is synthesized locally by lesion macrophages, and 
the local apoE expression by macrophages is atheroprotec-
tive (49). On the other hand, increased cellular ceramides 
have been reported to reduce macrophage-derived apoE 
secretion (demonstrated with the E3 phenotype) without 
increased cell retention of nascent apoE (50). Further-
more, apoE has been demonstrated to prefer binding on 
oxidized LDL loading-induced, ceramide-enriched micro-
domain surfaces of human macrophages, which could con-
tribute to atherogenesis (42). apoE has also been shown to 
prefer binding to ceramides compared with sphingomy-
elins (48), and SMase-stimulated ceramide formation can 
therefore induce the membrane remodeling activity of 
apoE and free cholesterol. If hypothesized, all of these 
reported findings would be related to the apoE parent 
isoform E3, and E2 or E4 might, therefore, present altered 
interactions worth investigating, possibly affecting athero-
genic processes via, for example, lipoprotein particle 
aggregation or adjustment of sphingolipid transfer balance 
in macrophages. In any case, apoE4 (but not E3) in 
macrophages has already been demonstrated to enhance 
atherosclerotic plaque development in an LDL receptor-
dependent manner (51).
Our study has several important strengths. Our study 
cohort has a long and systematic follow-up, offering a repre-
sentative cross-sectional sample of relatively young Finnish 
adults. In addition, the comprehensive background infor-
mation gathered from our cohort allowed for a thorough 
analysis and consideration of the most expected confound-
ing factors. Furthermore, our analyses reflect genotype- 
related differences in a basically healthy general population, 
avoiding confounding/confusing expressions of illnesses 
expected when using morbid study subjects. In addition, 
the modern and sophisticated mass spectrometry technol-
ogy enabled the measurement of circulating ceramides 
with good accuracy. We also acknowledge certain limita-
tions in our cross-sectional study. Our present scope did 
not allow direct analyses of subclinical atherosclerosis mea-
sures. As previously reported in the Finnish general popu-
lation (2, 52), subgroups of apoE 2/2, 4/2, and 4/4 
were also small in our population-based setting and did not 
allow for complete analyses of all six genotypes separately. 
In addition, a completely comprehensive comparison be-
tween (sex-stratified) men and women might require an 
even larger sample size for increased statistical power; how-
ever, the absence of apoE × sex interactions was confirmed 
in the analyses of all subjects. Nevertheless, based on refer-
ence studies (e.g., 2, 3), these recognized limitations are 
not expected to alter the effect directions related to differ-
ent apoE alleles and are thus less likely to have any major 
impact on the main discoveries presented and discussed 
here.
In conclusion, based on quantified molecular ceramide 
species from plasma, apoE polymorphism is associated with 
a risk of developing CAD, especially by indicating altered 
levels of the previously reported clinical high-risk marker 
Cer(d18:1/16:0) in all subjects. Furthermore, the concen-
tration of every apoE-associating ceramide species in our 
study has been reported to be reduced in LDL and VLDL 
particles by PCSK9 inhibition (44), whereas excessive 
sphingolipid loading has been reported to promote CAD 
death (40). These findings suggest a plausible linkage be-
tween ceramide metabolism, apoE polymorphism, plasma 
LDL metabolism, and atherogenesis. Changes have already 
been discovered in a basically healthy general population 
and extend our understanding of the role of apoE in health 
and disease. For further work, similar analyses could be 
performed with patients with incident CAD and established 
CAD to discover whether the observed associations of apoE 
polymorphism would change. Associations with subclinical 
atherosclerosis measures (e.g., carotid artery intima-media 
thickness or plaques) should also be investigated for fur-
ther indications. In addition, longitudinal follow-up studies 
could be performed with older test subjects. Furthermore, 
the effects of apoE polymorphism on the sphingolipid/ce-
ramide metabolism pathway might be worth investigating, 
such as whether the macrophage functions or lipoprotein 
aggregation tendency would become different depending 
on the apoE isoform. Additional inflammatory marker cor-
relations might also be worth investigating, and the ce-
ramide levels could also be correlated with sphingomyelinase 
activities.
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